Medicenna Therapeutics Corp.
MDNA
|
$0.157
-0.32%
1.3M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-76.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (167.34% volume)
Earnings Calendar: 2023-10-26
Market Cap: $ 10,933,083
http://www.medicenna.com
Sec Filling | Patents | 7 employees
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
cancer treatment
add to watch list Paper trade email alert is off
Press-releases
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
MDNAF | $1.14 -17.54% 58K
|
n/a
| Email alert
Add to watchlist
mdna11 presentation asco meeting study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 ongoing expansion results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: -3.82%
H: 0.0%
C: -13.49%
mdna113 association cancer research preclinical for meeting
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: -4.01%
H: 9.01%
C: -3.43%
conference
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 3.0%
H: 6.12%
C: 0.36%
mdna11 association update cancer research meeting trial
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
Published: 2024-02-14 (Crawled : 12:30) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 2.95%
H: 29.02%
C: 23.53%
update therapeutics financial results
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 2.04%
H: 2.8%
C: -0.92%
mdna11 keytruda first tumors advanced study
Medicenna Announces Appointment of New Auditor
Published: 2024-01-12 (Crawled : 23:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
MDNAF | $1.14 -17.54% 58K
|
n/a
| Email alert
Add to watchlist
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10